Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 2/20 | 0.55 |
| ▸ | GRM6 | O15303 | 2/20 | 0.55 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.55 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.55 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.55 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.55 |
| ▸ | GSR | P00390 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.55 |
| ▸ | GRM5 | P41594 | 1/20 | 0.55 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.55 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.55 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.55 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.55 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.55 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1768346 | 1.00 | GRM8 (0.55) | GRM8GRM6GRM7GRM4GRIN2D | |
| SCHEMBL31105501 | 0.83 | GLO1 (0.57) | GLO1 | |
| SCHEMBL31105462 | 0.83 | GLO1 (0.57) | GLO1 | |
| SCHEMBL31105602 | 0.83 | GLO1 (0.57) | GLO1 | |
| SCHEMBL31072581 | 0.83 | GLO1 (0.57) | GLO1 | |
| SCHEMBL31105585 | 0.83 | GLO1 (0.57) | GLO1 | |
| SCHEMBL31105479 | 0.83 | GLO1 (0.57) | GLO1 | |
| SCHEMBL31072576 | 0.83 | GLO1 (0.57) | GLO1 | |
| SCHEMBL31105389 | 0.83 | GLO1 (0.57) | GLO1 | |
| SCHEMBL25355764 | 0.81 | GRM8 (0.59) | GRM8GRM6GRM7GRM4GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754038-B2 | Template-fixed peptidomimetics with CCR10 antagonistic activity | POLYPHOR AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| EP-2501715-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | Polyphor Ag (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011060937-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011060832-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| US-5561133-A | Thymidylate synthase inhibiting quinazolinones | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1996-10-01 | — | — | US | disclosed |
| EP-0631576-A1 | DIPEPTIDYLQUINAZOLONES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 1995-01-04 | — | — | EP | disclosed |
| WO-1993019051-A1 | DIPEPTIDYLQUINAZOLONES AS ANTI-CANCER AGENTS | BRITISH TECHNOLOGY GROUP LTD (GB) | 1993-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | CCR10, CCR1, CCRL2 | GRM8 1650/4885GRM6 1857/4885GRM7 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.